828 related articles for article (PubMed ID: 28286921)
21. Intervention in gastro-enteropancreatic neuroendocrine tumours.
Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
[TBL] [Abstract][Full Text] [Related]
22. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors.
Koffas A; Toumpanakis C
Expert Opin Drug Saf; 2021 Mar; 20(3):321-334. PubMed ID: 33338383
[No Abstract] [Full Text] [Related]
23. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
Scoville SD; Cloyd JM; Pawlik TM
Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
[No Abstract] [Full Text] [Related]
24. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
[No Abstract] [Full Text] [Related]
26. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
27. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
30. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
Ye C; Yuan CH; Li G; Zheng L; Xiu DR
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
[TBL] [Abstract][Full Text] [Related]
31. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
33. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
34. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
35. Update in the Therapy of Advanced Neuroendocrine Tumors.
Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S
Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892
[TBL] [Abstract][Full Text] [Related]
36. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
37. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
38. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.
Alexandraki KI; Kaltsas G
Endocrine; 2012 Feb; 41(1):40-52. PubMed ID: 22124940
[TBL] [Abstract][Full Text] [Related]
39. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review.
Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525
[TBL] [Abstract][Full Text] [Related]
40. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
